View in EDS HTML Full Text PDF Full Text

Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions.

Saved in:
Bibliographic Details
Title: Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions.
Authors: Pierre CN; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Duke University School of Medicine, Durham, North Carolina, United States of America., Adams LE; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Higgins JS; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Anasti K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America., Goodman D; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America., Mielke D; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America., Stanfield-Oakley S; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America., Powers JM; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Li D; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America., Rountree W; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America., Wang Y; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America., Edwards RJ; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America., Alam SM; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America., Ferrari G; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, United States of America., Tomaras GD; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, United States of America.; Department of Immunology, Duke University, Durham, North Carolina, United States of America., Haynes BF; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Immunology, Duke University, Durham, North Carolina, United States of America., Baric RS; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Saunders KO; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, United States of America.; Department of Immunology, Duke University, Durham, North Carolina, United States of America.
Source: PLoS pathogens [PLoS Pathog] 2024 Jun 20; Vol. 20 (6), pp. e1011569. Date of Electronic Publication: 2024 Jun 20 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38900807
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Pierre+CN%22">Pierre CN</searchLink>; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Duke University School of Medicine, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Adams+LE%22">Adams LE</searchLink>; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Higgins+JS%22">Higgins JS</searchLink>; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Anasti+K%22">Anasti K</searchLink>; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Goodman+D%22">Goodman D</searchLink>; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Mielke+D%22">Mielke D</searchLink>; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Stanfield-Oakley+S%22">Stanfield-Oakley S</searchLink>; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Powers+JM%22">Powers JM</searchLink>; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Li+D%22">Li D</searchLink>; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Rountree+W%22">Rountree W</searchLink>; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Edwards+RJ%22">Edwards RJ</searchLink>; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Alam+SM%22">Alam SM</searchLink>; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Ferrari+G%22">Ferrari G</searchLink>; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Tomaras+GD%22">Tomaras GD</searchLink>; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, United States of America.; Department of Immunology, Duke University, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Haynes+BF%22">Haynes BF</searchLink>; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Immunology, Duke University, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Baric+RS%22">Baric RS</searchLink>; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Saunders+KO%22">Saunders KO</searchLink>; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, United States of America.; Department of Immunology, Duke University, Durham, North Carolina, United States of America.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101238921%22">PLoS pathogens</searchLink> [PLoS Pathog] 2024 Jun 20; Vol. 20 (6), pp. e1011569. <i>Date of Electronic Publication: </i>2024 Jun 20 (<i>Print Publication: </i>2024).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Public+Library+of+Science%22">Public Library of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101238921 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1553-7374 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215537366%22">15537366 </searchLink><i>NLM ISO Abbreviation: </i>PLoS Pathog <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38900807
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1371/journal.ppat.1011569
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e1011569
    Titles:
      – TitleFull: Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Pierre CN
      – PersonEntity:
          Name:
            NameFull: Adams LE
      – PersonEntity:
          Name:
            NameFull: Higgins JS
      – PersonEntity:
          Name:
            NameFull: Anasti K
      – PersonEntity:
          Name:
            NameFull: Goodman D
      – PersonEntity:
          Name:
            NameFull: Mielke D
      – PersonEntity:
          Name:
            NameFull: Stanfield-Oakley S
      – PersonEntity:
          Name:
            NameFull: Powers JM
      – PersonEntity:
          Name:
            NameFull: Li D
      – PersonEntity:
          Name:
            NameFull: Rountree W
      – PersonEntity:
          Name:
            NameFull: Wang Y
      – PersonEntity:
          Name:
            NameFull: Edwards RJ
      – PersonEntity:
          Name:
            NameFull: Alam SM
      – PersonEntity:
          Name:
            NameFull: Ferrari G
      – PersonEntity:
          Name:
            NameFull: Tomaras GD
      – PersonEntity:
          Name:
            NameFull: Haynes BF
      – PersonEntity:
          Name:
            NameFull: Baric RS
      – PersonEntity:
          Name:
            NameFull: Saunders KO
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 20
              M: 06
              Text: 2024 Jun 20
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1553-7374
          Numbering:
            – Type: volume
              Value: 20
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: PLoS pathogens
              Type: main
ResultId 1